Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
Recursion Pharmaceuticals expanded its collaboration with Citeline to integrate real world data into its AI enabled ClinTech Platform. The partnership is aimed at refining clinical trial design and ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Community driven content discussing all aspects of software development from DevOps to design patterns. The factorial of 5 is 120. The factorial of 10 is 3,628,800. Programmers can take one of two ...
Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...
Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results